secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edwards Lifesciences Corp (EW)
CIK:        0001099800
Form:       8-K
Filed at:   2025-10-30T23:59:59+00:00
Accession:  0001099800-25-000059
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edwards Q3 sales rise 14.7% to $1.55B; raises FY EPS guidance to $2.56-$2.62
----------------------------------------------------------------------------

- Q3 sales $1.55B (+14.7% YoY); adjusted EPS $0.67 vs $0.50 GAAP.
- TAVR sales $1.15B (+12.4%); TMTT sales $145.2M (+59.3%).
- Raised FY2025 adjusted EPS guidance to $2.56-$2.62 from high end of $2.45-$2.55.
- Raised TAVR sales growth guidance to 7-8% from 6-7%; total sales growth to high end of 9-10%.
- Board increased share repurchase authorization to $2.1B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1099800/000109980025000059/0001099800-25-000059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1099800/000109980025000059/ew-20251030.htm
  HTML page:      https://secwatch.observer/filing/0001099800-25-000059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer